| HOME >> MEDICINE >> TECHNOLOGY |
Overall Clinical Research Activity Just Below Record High
PAREXEL's analysis also includes an assessment of the number of active commercial INDs at the FDA Center for Drug Evaluation and Research (CDER), which is an indicator of overall clinical research activity. At the end of 2007, 5,417 active commercial INDs were being managed by CDER, compared to 5,445 at the end of 2006. "Our analysis shows that following a steady climb in recent years, the total number of active FDA-regulated INDs declined very slightly by a half percent in 2007, which was just below the record high," notes Mr. Mathieu.
About PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook
PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook, 2008/2009 is a leading compendium providing new insights into the trends that are reshaping the biopharmaceutical industry. Supported by thousands of graphs, illustrations, and analyses, the compendium provides the latest intelligence on every aspect of biopharmaceutical development-from product discovery to R&D performance and productivity to time-to-market trends.
With key analyses and contributions from leading consultancies and experts, the compendium provides real-world data and analyses, including:
-- New analysis of the countries in which biopharmaceutical companies are locating clinical studies
-- New global R&D spending trends and other international R&D data from key markets
-- International statistics on drug development output
-- Emerging data on worldwide and company-specific R&D pipelines and product launch trends
-- New
'/>"/>
| SOURCE PAREXEL International Corporation Copyright©2008 PR Newswire. All rights reserved |